PRAMEF1

Across TCGA pan-cancer cohorts, PRAMEF1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRAMEF1 data layer compared with 9 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRAMEF1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRAMEF1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM and OV are the cancer types where PRAMEF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.517	0.242	.002	13	view →
OV	DFS	Median	All	0.845	1.000	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRAMEF1–GBM (DFS)

Open the GBM breakdown →